AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies and through distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, the UK.
AstraZeneca Plc Key Recent Developments
Mar 31,2017: First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal
Mar 28,2017: Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
Mar 06,2017: Changes to AstraZeneca Board of Directors
Feb 02,2017: Astrazeneca Announces Full-Year and Q4 2016 Results
Jan 18,2017: AstraZeneca Receives 2017 CSO50 Award for use of Skyhigh Networks in Cloud Security Project
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
AstraZeneca Plc - Key Facts 6
AstraZeneca Plc - Key Employees 7
AstraZeneca Plc - Key Employee Biographies 8
AstraZeneca Plc - Major Products and Services 9
AstraZeneca Plc - Pharmaceutical Pipeline Products Data 12
AstraZeneca Plc, Pipeline Products by Therapy Area 12
AstraZeneca Plc, Pipeline Products by Development Phase 14
AstraZeneca Plc - History 15
AstraZeneca Plc - Company Statement 35
AstraZeneca Plc - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Joint Venture 42
Section 2 – Company Analysis 43
AstraZeneca Plc - Business Description 43
AstraZeneca Plc - Corporate Strategy 45
AstraZeneca Plc - SWOT Analysis 46
SWOT Analysis - Overview 46
AstraZeneca Plc - Strengths 46
AstraZeneca Plc - Weaknesses 47
AstraZeneca Plc - Opportunities 48
AstraZeneca Plc - Threats 50
AstraZeneca Plc - Key Competitors 51
Section 3 – Company Financial Ratios 52
Financial Ratios - Capital Market Ratios 52
Financial Ratios - Annual Ratios 53
Performance Chart 55
Financial Performance 55
Financial Ratios - Interim Ratios 56
Financial Ratios - Ratio Charts 57
Section 4 – Company’s Lifesciences Financial Deals and Alliances 58
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 58
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 59
AstraZeneca Plc, Recent Deals Summary 60
Section 5 – Company’s Recent Developments 61
Mar 31, 2017: First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal 61
Mar 28, 2017: Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 62
Mar 06, 2017: Changes to AstraZeneca Board of Directors 64
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 65
Nov 30, 2016: EPSRC Grant for Organic Synthesis with the University of York 66
Nov 14, 2016: Harnessing personalised healthcare to identify novel therapeutic targets for Chronic Kidney Disease patients 67
Nov 10, 2016: AstraZeneca: Year-To-Date and Q3 2016 Results 68
Nov 09, 2016: Change To Astrazeneca Board Of Directors 80
Nov 02, 2016: A new role for IGF1 signalling in driving fat tissue formation in heart disease 81
Oct 28, 2016: New data shows frequent ICU admissions from severe RSV disease among preterm infants in the first three months of life 82
Section 6 – Appendix 83
Methodology 83
Ratio Definitions 83
About GlobalData 87
Contact Us 87
Disclaimer 87List of Tables
AstraZeneca Plc, Key Facts 6
AstraZeneca Plc, Key Employees 7
AstraZeneca Plc, Key Employee Biographies 8
AstraZeneca Plc, Major Products and Services 9
AstraZeneca Plc, Number of Pipeline Products by Therapy Area 12
AstraZeneca Plc, Number of Pipeline Products by Therapy Area (Cont...1) 13
AstraZeneca Plc, Number of Pipeline Products by Development Stage 14
AstraZeneca Plc, History 15
AstraZeneca Plc, Subsidiaries 37
AstraZeneca Plc, Joint Venture 42
AstraZeneca Plc, Key Competitors 51
AstraZeneca Plc, Ratios based on current share price 52
AstraZeneca Plc, Annual Ratios 53
AstraZeneca Plc, Annual Ratios (Cont...1) 54
AstraZeneca Plc, Interim Ratios 56
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 58
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 59
AstraZeneca Plc, Recent Deals Summary 60
Currency Codes 83
Capital Market Ratios 83
Equity Ratios 84
Profitability Ratios 84
Cost Ratios 85
Liquidity Ratios 85
Leverage Ratios 86
Efficiency Ratios 86List of Figures
AstraZeneca Plc, Pipeline Products by Therapy Area 12
AstraZeneca Plc, Pipeline Products by Development Phase 14
AstraZeneca Plc, Performance Chart (2012 - 2016) 55
AstraZeneca Plc, Ratio Charts 57
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 58
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 59
Takeda Pharmaceutical Company Ltd
Shire Plc
Sanofi
Pfizer Inc
Novo Nordisk A/S
Novartis AG
Merck & Co Inc
Johnson & Johnson
GlaxoSmithKline Plc
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Company Ltd
Bristol-Myers Squibb Company
Astellas Pharma Inc
Amgen Inc
AbbVie Inc
